Re-bound at full text: no published experiment removes LEDGF from an established KMT2A-rearranged leukaemia in an animal - the tight intersection returns 12 records of which 6 are congress abstract books and none is a treatment experiment
also called Q115 LEDGF removal re-bound
Every published experiment that takes LEDGF away does so before or as the leukaemia forms, never after it is established in an animal, and reading whole papers rather than summaries does not change that. Half of what the search returns are conference programmes.
The same thing, for a scientist
The entry's distinction is prevention versus treatment: LEDGF removal before or at transformation is well covered, removal from an already-transformed leukaemia exists only *in vitro*. Re-run at full text with a five-alias LEDGF group (`PSIP1`, `LEDGF`, `LEDGF/p75`, `DFS70`, `lens epithelium-derived growth factor`): the group alone returns **2,779**, crossed with a seven-term KMT2A clause **357**, adding an in-vivo-model clause **124**, and crossed with established-disease phrases **12** [E1]. All 12 titles were read: **6 are congress abstract books**, three are autoimmune-serology papers reached through the DFS70 alias, one is a 9p deletion-syndrome review, and the two on-topic records are **PMID 39887730** (*Int J Cancer* 2026, a menin-KMT2A targeting review) and **PMID 28609655** (*Cancer Cell* 2017, *MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged AML*) - neither a LEDGF-removal treatment experiment [E1]. **The absence survives.**
The DFS70 alias is a contaminant and it should be recorded as one
Three of the twelve hits - Machine learning identifies clusters of longitudinal autoantibody profiles predictive of SLE outcomes (Ann Rheum Dis 2023), Environment and systemic autoimmune rheumatic diseases (Front Immunol 2024) and Autoantibody Discovery, Assay Development and Adoption (Front Immunol 2021) - are autoimmune serology, because DFS70 is the name of an anti-nuclear-antibody staining pattern as well as an alias of PSIP1. At full text that alias pulls in a rheumatology literature that shares no biology with this beat.
The entry's own aliases_excluded list already rejects p75 (p75NTR collision) and p52 (a different isoform). DFS70 belongs on that list for full-text searching, though not necessarily for [tiab], where the entry's counts were small enough to title-check. This is offered as a registry candidate.
| script | none - Europe PMC BODY: queries, 2026-09-22 |
|---|---|
| status | run |
| verdict | SURVIVES at full text on the tight query; the 124-record in-vivo intersection is an UNSCREENED upper bound |
| entry re bounded | absence-ledgf-removal-from-established-kmt2a-leukaemia |
| instrument before | abstract-level queries with NO field tag at all, so they ran as All Fields |
| instrument after | four full-text intersections; 12 read in full, 124 not screened |
| absence class | never-measured |
| absence class basis | UNCHANGED. An experiment nobody performed leaves no deposit, and no archive query applies to 'was a drug given to an animal with established disease'. |
queries — the numbers behind the chart
[
{
"q": "LEDGF alias group",
"hits": 2779,
"role": "operand control"
},
{
"q": "LEDGF group AND KMT2A clause",
"hits": 357
},
{
"q": "LEDGF group AND KMT2A clause AND in-vivo model terms",
"hits": 124,
"screened": false
},
{
"q": "LEDGF group AND established-disease phrases",
"hits": 12,
"read": 12,
"on_topic": 0,
"proceedings": 6
}
]aliases searched
[ "PSIP1", "LEDGF", "LEDGF/p75", "DFS70", "lens epithelium-derived growth factor" ]
new alias trap
{
"alias": "DFS70",
"problem": "also the name of an anti-nuclear-antibody staining pattern; pulled 3 of 12 hits from rheumatology at full text",
"recommendation": "exclude DFS70 from full-text LEDGF queries; registry candidate, NOT added by this beat"
}- The 124-record LEDGF x KMT2A x in-vivo intersection was never screened, and it is where a treatment experiment would be. Reading those titles is the unfinished half of this re-bound.
- Would 'after engraftment', 'disease burden' or 'treatment setting' phrasings find an experiment the four established-disease phrases missed?
- Should DFS70 be excluded from full-text LEDGF queries corpus-wide? It contaminated a quarter of this hit list.
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.database
At full text the LEDGF alias group returns 2,779 records, 357 with a KMT2A clause, 124 with an in-vivo-model clause and 12 with established-disease phrases; all 12 were read and none is a LEDGF-removal experiment in an established leukaemia, with 6 being congress abstract books and 3 reached through the DFS70 autoantibody alias.
Europe PMC RESTful search, BODY: LEDGF aliases x KMT2A clause x established-disease phrases, 2026-09-22 · Europe PMC 2026What this evidence cannot show
Europe PMC BODY: reaches only the 12,362,145 full texts the index holds, so a paywalled paper remains invisible. A congress abstract book is one document holding thousands of unrelated abstracts and matches almost any conjunction; across this beat's 18 fully-read intersections 83 of 321 records (25.9%, range 0-50%) are proceedings. Screening was at TITLE level unless a paper is listed as opened. The established-disease phrase list has four members - established leukemia, established leukaemia, established disease, after leukemia onset - and it is the bound. A paper writing 'in mice with detectable disease burden', 'after engraftment' or 'in a treatment setting' would not match, and those are common phrasings. The 124-record in-vivo intersection was NOT title-screened and is an upper bound.
Evidence that argues against this (1)
- The 124-record intersection of LEDGF aliases, a KMT2A clause and xenograft/NSG/secondary-transplant terms is the set that would actually contain a treatment experiment, and it was not read. Twelve screened records cannot bound a claim that 124 records are relevant to. This re-bound is therefore weaker than the others in this tranche and says so. Europe PMC 2026
SURVIVES at full text on the tight query (12 records, 6 proceedings, 0 on topic); the 124-record in-vivo intersection is an unscreened upper bound
DFS70, one of this gene's aliases, is also an anti-nuclear-antibody staining pattern and contaminated a quarter of the full-text hit list